Jade Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Jade Biosciences, Inc. (JBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.49 million shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-03-27
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-30 was 92.50K shares, a 47.89% decline year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 1.40M shares, a 20.56% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.49M shares, a 3.67% decline from fiscal 2023.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.55M shares, a 61.96% increase from fiscal 2022.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 954.56K shares, a 70.40% decline from fiscal 2021.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 3.23M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-27 | 92.50K shares derived: sum of 3 quarters · filed 2025-03-27 | 1.49M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 92.50K shares derived: sum of 2 quarters · filed 2024-11-12 | 1.49M shares 10-Q · filed 2024-11-12 | 1.57M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 92.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 1.49M shares 10-Q · filed 2024-08-12 | 1.57M shares derived: sum of 3 quarters · filed 2024-08-12 | 1.70M shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 1.40M shares 10-Q · filed 2024-05-13 | 1.48M shares derived: sum of 2 quarters · filed 2024-05-13 | 1.61M shares derived: sum of 3 quarters · filed 2024-05-13 | 1.78M shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 85.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 210.00K shares derived: sum of 2 quarters · filed 2024-03-25 | 387.50K shares derived: sum of 3 quarters · filed 2024-03-25 | 1.55M shares 10-K · filed 2024-03-25 |
| 2023-09-30 | 125.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 302.50K shares derived: sum of 2 quarters · filed 2023-11-13 | 1.46M shares 10-Q · filed 2023-11-13 | 1.62M shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 177.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 1.34M shares 10-Q · filed 2023-08-14 | 1.50M shares derived: sum of 3 quarters · filed 2023-08-14 | 1.78M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 1.16M shares 10-Q · filed 2023-05-15 | 1.32M shares derived: sum of 2 quarters · filed 2023-05-15 | 1.61M shares derived: sum of 3 quarters · filed 2023-05-15 | 1.86M shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 160.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 447.50K shares derived: sum of 2 quarters · filed 2023-03-29 | 705.00K shares derived: sum of 3 quarters · filed 2023-03-29 | 954.56K shares 10-K · filed 2023-03-29 |
| 2022-09-30 | 287.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 545.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 794.56K shares 10-Q · filed 2022-11-14 | 1.45M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 257.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 507.06K shares 10-Q · filed 2022-08-15 | 1.16M shares derived: sum of 3 quarters · filed 2022-08-15 | 1.19M shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 249.56K shares 10-Q · filed 2022-05-16 | 903.36K shares derived: sum of 2 quarters · filed 2022-05-16 | 932.98K shares derived: sum of 3 quarters · filed 2022-05-16 | |
| 2021-12-31 | 653.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 683.42K shares derived: sum of 2 quarters · filed 2022-03-30 | 3.23M shares 10-K · filed 2022-03-30 | |
| 2021-09-30 | 29.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 2.57M shares 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | 2.54M shares 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |